THE COMPARATIVE EFFECTIVENESS OF CYCLING TUMOURNECROSIS FACTOR INHIBITOR (TNFI) VERSUS SWAPPING TO A NONTNFI ON PATIENT-REPORTED FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Lopez-Oliva, M. A. [1 ]
Matusevich, A. [1 ]
Cantor, S. B. [2 ]
Pratt, G. [3 ]
Suarez-Almazor, M. E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Gen Internal Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Hlth Serv Res, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Res Med Lib, Houston, TX 77030 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.6989
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0298
引用
收藏
页码：196 / 196
页数：1
相关论文
共 50 条
  • [41] ORAL START: EFFECTS OF THE ORAL JAK INHIBITOR TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN THE PHASE 3 ORAL START TRIAL OF ACTIVE RHEUMATOID ARTHRITIS
    Strand, V.
    Fleischmann, R.
    Alten, R. E.
    Koncz, T.
    Zwillich, S. H.
    Bradley, J. D.
    Gruben, D.
    Wilkinson, B.
    Krishaswami, S.
    Wallenstein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 252 - 253
  • [42] Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
    Rieke Alten
    Gerd R. Burmester
    Marco Matucci-Cerinic
    Jean-Hugues Salmon
    Andrew Östör
    Khai Jing Ng
    Jens Gerwien
    Liliana Zaremba-Pechmann
    Alan J. M. Brnabic
    Bruno Fautrel
    Rheumatology and Therapy, 2023, 10 : 1575 - 1595
  • [43] Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials
    Wallenstein, G. V.
    Kanik, K. S.
    Wilkinson, B.
    Cohen, S.
    Cutolo, M.
    Fleischmann, R.
    Genovese, M. C.
    Gomez Reino, J.
    Gruben, D.
    Kremer, J.
    Krishnaswami, S.
    Lee, E. B.
    Pascual-Ramos, V.
    Strand, V.
    Zwillich, S. H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 430 - 442
  • [44] Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs
    Henriksson, Kenneth
    From, Jesper
    Stratelis, Georgios
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1611 - 1617
  • [45] Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study.
    Finckh, Axel
    Gottenberg, Jacques-Eric
    Mpofu, Chiedzo
    Bensen, William G.
    Rubbert-Roth, Andrea
    Irazoque, Fedra
    Martinez Taboada, Victor
    Chung, Carol
    Hinsch-Gylvin, Lykke
    Ferri, Clodoveo
    Emery, Paul
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S198 - S198
  • [46] RANDOMIZATION TO PATIENT-REPORTED RAPID3 VERSUS PHYSICIAN-BASED CDAI TOOLS FOR PREDICTION OF TREATMENT RESPONSE AND ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB PEGOL: RESULTS FROM THE PREDICT STUDY
    Curtis, J. R.
    Churchill, M.
    Kivitz, A.
    Samad, A.
    Gauer, L.
    Coteur, G.
    Gervitz, L.
    Koetse, W.
    Melin, J.
    Yazici, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 382 - 382
  • [47] PATIENT-REPORTED OUTCOMES FROM A PHASE 3 STUDY OF BARICITINIB VERSUS PLACEBO OR ADALIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO BACKGROUND METHOTREXATE THERAPY
    Keystone, E.
    Taylor, P.
    Tanaka, Y.
    Gaich, C.
    DeLozier, A. M.
    Dudek, A.
    Zamora, J. Velasco
    Cobos, J. Covarrubias
    De Bono, S.
    Arora, V.
    Yang, L.
    Linetzky, B.
    Weinblatt, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 412 - 413
  • [48] The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
    Harrold, Leslie R.
    Reed, George W.
    Kremer, Joel M.
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Hochberg, Marc C.
    Greenberg, Jeffrey D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 430 - 436
  • [49] TARGET SETTING OF FUNCTIONAL REMISSION FOR HAND AND WRIST SURGERIES USING GRIP POWER AND PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY
    Ishikawa, Hajime
    Abe, Asami
    Kojima, Toshihisa
    Kojima, Masayo
    Kurosawa, Yoichi
    Hasegawa, Eriko
    Ito, Satoshi
    Ishiguro, Naoki
    Murasawa, Akira
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1587 - 1588
  • [50] Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
    Pappas, Dimitrios A.
    St John, Gregory
    Etzel, Carol J.
    Fiore, Stefano
    Blachley, Taylor
    Kimura, Toshio
    Punekar, Rajeshwari
    Emeanuru, Kelechi
    Choi, Jeannie
    Boklage, Susan
    Kremer, Joel M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (01) : 96 - 102
12345